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Abstract
Staphylococcus aureus, in spite of antibiotics, is still a major human pathogen causing a wide range of infections. The
present study describes the new vaccine A170PG, a peptidoglycan-based vaccine. In a mouse model of infection, A170PG
protects mice against a lethal dose of S. aureus. Protection lasts at least 40 weeks and correlates with increased survival and
reduced colonization. Protection extends into drug-resistant (MRSA or VISA) and genetically diverse clinical strains. The
vaccine is effective when administered - in a single dose and without adjuvant - by the intramuscular, intravenous or the
aerosol routes and induces active as well as passive immunization. Of note, A170PG also displays therapeutic activity,
eradicating staphylococci, even when infection is systemic. Sustained antibacterial activity and induction of a strong and
rapid anti-inflammatory response are the mechanisms conferring therapeutic efficacy to A170PG.
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Introduction
S aureus has developed a successful strategy of evading the
human immune system, entailing the accumulation of an
impressive array of virulence factors. It can colonize several niches
of the human body and cause life-threatening diseases, such as
pneumonia, osteomyelitis, septicaemia and endocarditis. S. aureus
infects immunocompromised patients as well as patients without
apparent risk factors [1]. About 30% of the human population
carries S. aureus [2], a circumstance testifying the ability of this
pathogen to modulate its virulence and to colonize the human
host.
Strain differences in the resistance to S. aureus infection have
been demonstrated in mice [3]. There is suggestive evidence that
individual differences in the defence against S. aureus might also
exist in humans. A polymorphism in the TIR domain of the
human TLR2 gene has been reported to be associated with S.
aureus susceptibility [4], although this association was not
confirmed in a later study [5]. In addition to the capacity to
cause diverse and serious diseases, S. aureus also displays an
extraordinary potential to develop antimicrobial resistance [6].
The last decade has witnessed the emergence and rapid spread of
community-associated and antibiotic-resistant strains [1]. In this
context, the development of an effective vaccine appears
particularly urgent.
The present article exploits the use of S aureus peptidoglycan
(PG) as a potential vaccine. PG, a linear polymer of repeating -1-4-
linked N-acetylglucosamine and N-acetylmuramic acid, accounts
for approximately 50% in weight of the cell wall of Gram-positive
bacteria, enabling them to resist osmotic pressure [7]. The S. aureus
PG is recognized by the host nucleotide-binding oligomerization
domain (Nod) 1 and Nod 2 [7] intracellular receptors and is
involved in the activation of the complement [8], cell-mediated
immunity [9] and opsonization [8]. PG is present on all the S.
aureus bacterial strains, is exposed on the cell wall and can thus
sense the external environment [8]. These features make it
attractive as a vaccine.
This paper presents evidence that the PG-based vaccine
A170PG, administered by the intramuscular, intravenous or
aerosol routes in a single dose and without adjuvant, protects
mice against an otherwise lethal dose of S. aureus. Protection lasts at
least 40 weeks and extends to S. epidermidis and L. monocytogenes. The
serum from vaccinated mice protects naı ¨ve mice against a lethal
dose of S. aureus. Remarkably, the vaccine, administered to already
infected mice, eradicates infection in one month.
Results
Peptidoglycan protects mice against S. aureus
The cell wall (CW) from the S. aureus strain A170 was extracted
with trichloroacetic acid [10] and preliminarily purified with
concanavalin A (ConA) -Agarose. Two groups of mice were then
immunized with the ConA negative (ConA
-CW) or the ConA
positive (ConA
+CW) fraction of the CW, respectively. Two weeks
later the mice were challenged with an otherwise lethal dose of S.
aureus A170. The mice immunized with the ConA
+CW fraction
survived all (10/10), while those immunized with the ConA
-CW
fraction died all (10/10) (Table 1; experiment 1; P: ,0.0001).
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conserved its protective activity intact, a result which makes
unlikely that protection was afforded by a glycoprotein with
affinity for ConA and co-purified with the CW (Table 1;
experiment 1; P: ,0.0001).
Mindful of drawbacks often associated with S. aureus CW
purification by chemical methods [11,12], the identification of the
ConA
+CW component protecting mice against S. aureus was
pursued by serological and enzymatic methods. Using as antigens
the ConA
+CW fraction, peptidoglycan (PG) and lipoteichoic acid
(LTA) from S. aureus, the serum from mice immunized with the
ConA
+CW preparation was shown to react with the homologous
antigen ConA
+CW (as expected), with PG, but not with LTA
(Figure 1, panel A). The test provided preliminary evidence that
PG, but not LTA, is present in the ConA
+CW preparation. The
absence of LTA is not surprising since presumably removed by the
trichloroacetic acid used to extract the CW [11].
The serum from mice immunized with the ConA
+CW
preparation protects naive mice from a lethal dose of A170. The
same serum lost this property if first absorbed with PG (Table 1;
experiment 2; P: ,0.0001). This result is the first line of evidence
that PG is the component affording protection.
The ConA
+CW preparation was digested with lysozyme or
lysostaphin. The enzyme-digested preparations were then tested to
see whether they conserved the capacity to protect mice
challenged with a lethal dose of the A170 strain. Digestion with
lysozyme or lysostaphin destroyed the ability of ConA
+CW to
immunize mice (Table 1; experiment 3; P: 1). Given that these
enzymes both hydrolyze specifically the PG [11,13], the result
provides further evidence that PG is indeed the ConA
+CW
component conferring protection against S. aureus.
The S. aureus strain A170 was grown in the presence of
penicillin G (5 mg/ml). When the culture reached the stationary
phase, the soluble PG (sPG) was isolated from the medium by
ConA-Sepharose affinity chromatography, tested for reactivity
with ConA
+CW antibodies (Figure 1, panel B) and used to
immunize mice. Challenged two weeks later with a lethal dose
of A170, the immunized mice survived all (10/10) (Table 1;
experiment 4; P: ,0.0001). Since sPG is deprived of any
CW component [11], the experiment provides compelling
evidence that the protection observed in this experiment is
afforded by PG.
Pentaglycine (Gl5) is an epitope unique to staphylococcal PG
[14,15] while muramic acid (MA) and ribitol (RBT) are
monosaccharides unique to PG and teichoic acid (TA), respec-
tively [11,15]. Gly5, MA and RBT were therefore ideal reagents to
confirm the presence of PG and the absence of TA in the
ConA
+CW preparation. In a direct ELISA assay, Gly5 and MA
bound to the ConA
+CW antibodies, while RBT did not (Figure 1,
panel B); similarly, in a competition test only Gly5 and MA, along
with PG, inhibited the binding of ConA
+CW antibodies to the
homologous antigen (Figure 1, panel C).
Taken together, the above experiments offer stringent and
independent lines of evidence that the component of ConA
+CW
conferring protection against S. aureus infection corresponds to the
PG; this component will be referred to as A170PG.
A170PG prevents S. aureus infection
Protection experiments with A170PG were extended to a larger
number of animals. To present the results more effectively, the
details of the experiments described in this and the following
sections are shown in the relevant tables or figure legends. Mice
were immunized with A170PG and two weeks later infected with a
lethal dose of S. aureus A170. At the time of infection, the antibody
titre against A170PG was 10
24–10
25. The vaccinated mice
survived (20/20), while control (non-vaccinated) mice died (20/
20) within 4–5 days (Table 2; experiment 1; P: ,0.0001). Four days
after challenge, the kidneys of the A170PG-treated animals
displayed significantly fewer CFU (log10 of CFU number:
4.763.6; P: ,0.0001) compared to the kidneys of the control mice.
Inspected four weeks after challenge, the kidneys of the vaccinated
mice were sterile (Table 2; experiment 1–2). When the interval
between vaccination and challenge was extended to 40 weeks,
A170PG was still protective (Table 2; experiment 2; P: ,0.0001).
Next experiments were aimed at optimizing the dose of the
vaccine. The smallest dose of A170PG tested – 3 mg/mouse – was
fully protective and safe, even when administered intravenously
(Table 3; experiments 1 and 2; P: ,0.0001; Figure S2). The
experiments to be described were all carried out using the dose of
3 mg/mouse.
Table 1. PG is the protective component of the ConA
+ CW fraction.
Interval Treatment-challenge:
weeks (w)/ hours (h) Challenge
a
Exp Dose/mouse Treatment Pathogen Survival P-value
b
11 5 mg ConA
+ CW 2 w A170 10/10 ,0.0001
15 mg ConA
- CW 2 w A170 0/10
15 mg Heat-treated ConA
+ CW 2 w A170 10/10 ,0.0001
A170 0/10
21 0 ml Non-absorbed ConA
+ CW Antibodies 24 h A170 10/10 ,0.0001
PG-Absorbed ConA
+ CW Antibodies 24 h A170 0/10
31 5 mg Lysozyme-Digested ConA
+ CW 2 w A170 0/10 1
15 mg Lysostaphin- Digested ConA
+ CW 2 w A170 0/10 1
41 5 mg sPG 2 w A170 10/10 ,0.0001
A170 0/10
a10
8 CFU/mouse.
bKaplan-Meier test.
doi:10.1371/journal.pone.0028377.t001
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The efficacy of the vaccine was also tested against 28
heterologous strains of S. aureus, 26 of which derived from patients
withstaphylococcalinfections. Strainsrepresentdifferentgenotypes,
as assessed by several approaches (Table S1). Mice were vaccinated
intramuscularly with 3 mg of A170PG and two weeks later were
infected by the same route with a lethal dose of one of the bacterial
strains. The difference in survival between vaccinated and control
miceatfourweeksfromchallengewasstatisticallysignificantineach
case (Table S2). At time of death (4–5 days from infection) the
kidneycolonizationlevelsamongcontrolmicerangedfrom 7.166.3
to 7.866.1 (log10 of CFU number). At four weeks from challenge
the kidneys of vaccinated mice were sterile. Remarkably, the
vaccine was effective against the methicillin-resistant (MRSA)
strainsA174,A175,RIMD31092andthevancomycin-intermediate
(VISA) strain A176 (Table S2). A170PG also protected mice against
the challenge with a lethal dose of the Gram-positive bacteria S.
epidermidis or L. monocytogenes (surviving mice: 10/10) (Table S2), a
result concurring with the broad cross-reaction displayed by the PG
preparations from S. aureus, S. epidermidis and L. monocytogenes (Figure
S1) and the evidence that PG is highly conserved among Gram
positive bacteria [16].
The A170PG antibodies protect against S. aureus
infection in vivo
Two groups of mice were injected intramuscularly with protein
A-purified Ig from normal mouse serum or from the serum of mice
immunized with A170PG (10 mla t5 0mg/ml diluted 1:10 with
sterile saline/mouse). The next day, the mice were challenged with
a lethal dose of S. aureus A170. Survival was monitored for seven
days. In two independent experiments, the serum from mice
immunized with A170PG antibodies protected mice from death
(20/20) (Table 4; experiments 1–2; P: ,0.0001). The same serum-
given at the dose of 20 ml/mouse - killed 20 out of 20 mice
(Table 4; experiments 3–4; P: 1). Absorption of A170PG
antibodies (10 mla t5 0ml/ml diluted 1:10 with saline) with rat
anti-total mouse immunoglobulin (5 ml at 100 mg/ml) or with
A170PG (5 ml at 100 mg/ml) abrogated the protective effect of the
Figure 1. The component of the A170PG vaccine affording protection is peptidoglycan. A. The serum from mice immunized with A170PG
reacts with the PG, but not with LTA, excluding that A170PG contains LTA. B. The serum from mice immunized with A170PG binds the homologous
antigen (A170PG); the sPG (deprived of any CW component); Gly5 and muramic acid (MA), both unique component of PG. The same serum does not
bind ribitol, specific to the teichoic acid. This result excludes that A170PG contains teichoic acid. C. Binding of the serum from mice immunized with
A170PG to the homologous antigen (A170PG) immobilized on the plate is quantitatively inhibited by muramic acid (MA), Gly5, sPG, A170PG, but not
ribitol.
doi:10.1371/journal.pone.0028377.g001
Table 2. A170PG, administered by the intramuscular route at 15 mg/mouse, protects mice against S. aureus infection.
Exp Vaccination
Interval vaccination/
challenge (weeks)
Challenge dose
(CFU/mouse) Pathogen Survival P- value
a
CFU/g kidneys
(mean±SD; log10)
Vaccine Dose (mg/mouse)
1 A170PG 15 2 10
8 A170 20/20 ,0.0001 0
b
10
8 A170 0/20 7.467
2 A170PG 15 40 10
8 A170 20/20 ,0.0001 0
b
10
8 A170 0/20 7.366.7
aKaplan-Meier test.
bCFU counted at 4 weeks from challenge.
doi:10.1371/journal.pone.0028377.t002
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demonstrate that protection afforded by the A170PG antibodies is
specific (is removed by rat anti total mouse immunoglobulin or the
homologous antigen); second, A170PG antibodies can be
protective or detrimental, depending upon the dose being given.
The A170PG vaccine eradicates lung infections
S. aureus is one of the most common causes of pneumonia [17]
and one of the bacterial pathogens most frequently detected in the
respiratory secretions of patients with cystic fibrosis [18]. To
explore the therapeutic potential of A170PG against lung
infection, groups of mice were infected via aerosol with the
A170 bacteria. Further, to ascertain whether the bacterial load
influenced the result, three different infection regimens were used
(10
6,1 0
7 or 10
8 CFU/mouse). When visibly sick (3–14 days from
infection, depending upon the infection regimen used), the mice
were treated with A170PG via aerosol (3 mgi n5 0ml/mouse). The
difference in survival between treated and untreated groups was
statistically significant in each case (Table 5; P: 0.0001 or
,0.0001). Remarkably, the lung colonization level was greatly
reduced at one week after treatment and infection eradicated in 30
days (Table 5); by this time, in addition to the lungs, also the liver,
kidneys and spleen of the treated mice were free from S. aureus
(Table S3).
Protective mechanisms elicited by the A170PG vaccine
Vaccines generally work by inducing antibodies with bacteri-
cidal activity, triggering a secondary response and preventing the
inflammation that follows infection. The A170 bacteria were
incubated (2 h at 37u) with (a) anti-A170WTA purified antibodies
alone, (b) complement alone or (c) with both antibodies and
complement. Bacteria were then plated and the CFU counted.
Antibodies alone exerted a bactericidal activity significantly
greater than that of the complement; when antibodies and
complement were used in combination, complement did not
enhance the bactericidal activity of the antibodies (Figure 2). Also,
Table 3. A170PG, administered by the intramuscular or the intravenous routs at 3 mg/mouse, protects mice against S. aureus.
Exp Vaccination Route
Challenge dose
(CFU/mouse) Pathogen Survival P- value
a
CFU/g kidneys
(mean±SD; log10)
Vaccine Dose (mg/mouse)
1 A170PG 3 Im
b 10
8 A170 10/10 ,0.0001 0
c
10
8 A170 0/10 7.266.1
2 A170PG 3 Iv
d 10
8 A170 10/10 ,0.0001 0
c
10
8 A170 0/10 7.466.3
aKaplan-Meier test.
bIntramuscular.
cCFU counted at 4 weeks from challenge.
dIntravenous.
doi:10.1371/journal.pone.0028377.t003
Table 4. A170PG antibodies protect mice against S. aureus strain A170.
Passive vaccination Challenge
Exp Treatment
Dose
(ml/mouse)
A170 Dose (CFU/
mouse) Survival P- value
a CFU/g
b (mean±SD; log10)
1 A170PG antibodies
c 10 10
8 20/20 ,0.0001 1.360
NMS-Ig
d 10 10
8 0/10 7.66 6.6
2 A170PG antibodies
c 10 10
8 20/20 ,0.0001 1.460.5
NMS-Ig
d 10 10
8 0/10 7.166.5
3 A170PG antibodies
c 20 10
8 0/20 1 6.165.1
NMS-Ig
d 20 10
8 0/10 7.766.3
4 A170PG antibodies
c 20 10
8 0/10 1 6.265.3
NMS-Ig
d 20 10
8 0/10 7.16 6
5 A170PG antibodies
c absorb-RamIg
e 10 10
8 0/10 1 7.86 6.3
NMS-Ig
d 10 10
8 0/10 7.666.3
6 A170PG antibodies
c absorb-A170PG
f 10 10
8 0/10 1 7.766
NMS-Ig
d 10 10
8 0/10 7.466.3
aKaplan-Meier test.
bColony forming units/g of kidneys; colony number calculated on 3 mice.
cA170 PG antibodies purified by affinity chromatography from mice vaccinated with 3 mg vaccine.
dImmunoglobulins purified by affinity chromatography from normal mouse serum.
eA170PG antibodies absorbed with rat anti total mouse immunoglobulin.
fA170PG antibodies absorbed with A170PG.
doi:10.1371/journal.pone.0028377.t004
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from the first, displayed the main features of the vaccine-induced B
cell memory: switch from the IgM to the IgG or IgA isotypes and
rapid antibody production (Figure 3). Mice, vaccinated and 2
weeks later infected, displayed a cytokine profile very similar to
that of naive mice; instead, the mice infected without being first
vaccinated displayed significantly higher levels of the pro-
inflammatory cytokines TNA-a (P: ,0.0001) and IFN-c (P:
0.01) compared to the levels of the vaccinated mice(Figure 4).
Finally, S. aureus colonized lungs or kidneys from non-vaccinated
mice, while was unable to colonize the same organs from
vaccinated mice (Figure 5).
The therapeutic activity of A170PG was also characterized
by a rapid reduction of the bacterial load and inflammation level
of treated mice. Mice, infected and 72 h later treated with
A170PG, returned free of S. aureus within 30 days from treatment
(Table 5; Table S3) and displayed significantly lower transcrip-
tion levels of the cytokines TNF-a (P: ,0.0001) and IFN-c (P:
0.03) compared to the mice which were infected, but not treated.
(Figure 4).
Table 5. Aerosol administration of A170PG vaccine (3 mg/mouse) eradicates the S. aureus lung infection.
Infection
regimen
Interval infection
treatment (days)
Colonization level (CFU±SD; log10)
at time of:
Colonization level (CFU±SD;
log10) at indicated days
from treatment
b Survival P-value
a
Mice Infection
b Treatment
b Death
b
71 4 3 0
Treated 10
8 35 . 3 65.0 6.866.4 4.763.3 2.661.6 0 9/10 0.0001
Untreated 10
8 5.465.1 7.265.8 0/10
Treated 10
7 94 . 5 64.3 6.766.3 4.763.6 2.361.5 0 10/10 ,0.0001
Untreated 10
7 4.464.2 7.366.1 0/10
Treated 10
6 14 3.763.3 6.865.6 4.663.5 2.361.7 0 10/10 ,0.0001
Untreated 10
6 3.863.2 7.265.3 0/10
aKaplan-Meier test.
bValues calculated on 3 mice.
doi:10.1371/journal.pone.0028377.t005
Figure 2. A170PG antibodies display strong bactericidal activity also in the absence of complement. A170 bacteria (10
7 CFU/100 ml TSB
medium) were incubated (1 h, 37uC) alone, with complement (5 ml), with purified A170PG antibodies (5 ml), or with complement (5 ml) and antibodies
(5 ml). Bacteria were cultured on agar plates and CFU counted. Each histogram represents the results (mean6SD) of 3 independent experiments.
doi:10.1371/journal.pone.0028377.g002
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In a mouse model of infection, the A170PG vaccine protects
mice against a lethal dose of S. aureus. Protection correlates with
increased survival and reduced colonization. It lasts at least 40
weeks (Table 2) and extends into genetically diverse (Tables S1)
and drug-resistant (MRSA or VISA) (Table S2) clinical strains.
The vaccine is effective when administered - in a single dose and
without adjuvant - by the intramuscular, intravenous (Table 3) or
aerosol (Table 5) routes. Significantly, A170PG eradicates the
pathogen by the time infection has become systemic (Table S3).
The vaccine induces active as well as passive immunization:
adoptively transferred A170PG antibodies protect mice against a
lethal S. aureus challenge (Table 4).
Several and independent experiments critically demonstrate
that the biologically active component of the vaccine is the PG.
First, the serum from vaccinated mice protects naive mice from a
lethal dose of A170; however, this property is lost if the serum is
absorbed with PG ( Table 1, experiment 2). Second, the vaccine
loses the capacity to protect mice if first digested with lysozyme or
lysostaphin, enzymes which hydrolyze specifically the PG (Table 1,
experiment 3). Third, grown in the presence of penicillin G (which
inhibits the PG incorporation into the CW), the PG accumulates
in the culture medium in a soluble form (sPG) deprived of any CW
component [11]; the sPG from the A170 strain effectively protects
mice against S. aureus (Table 1, experiment 4). Fourth, the serum
from mice vaccinated with A170PG recognizes two components
unique of the PG: Gl5 and MA (Figure 1, panel B).
The results described in this study, while promising, require a
critical analysis in the light of the current literature. The mouse
strain used in this study (Balb/c) is highly susceptible to S. aureus
[3]. Still, large bacterial doses are needed for infection. The model
therefore does not mimic closely human staphylococcal infections,
which are generally caused by a small initial inoculum. Second,
unlike humans, the mouse does not have pre-existing antibodies to
S. aureus [19]. Therefore, one must contemplate the possibility that
A170PG - which works well in mice - might not work equally well
in humans since it could be neutralized by pre-existing antibodies.
More important, there is evidence that staphylococcal escape
strategies from immune defence mechanisms are by far more
efficient in humans than in mice [20].
PG shows limited serological variability [16] (Figure S1),
confirmed by the capacity of A170PG to protect against S. aureus,
S. epidermidis and L. monocytogenes (Table S2). PG thus represents an
attractive choice as vaccine. However, previous single component
vaccines have given disappointing results in humans [19].
StaphVAX (a capsular polysaccharide vaccine) in the confirma-
tory phase III clinical trial offered no significant protection against
S. aureus, compared to the control group [19]. Thus, the efficacy of
Figure 3. Upon receiving a second dose of the A170PG vaccine,
mice undergo antibody isotype switch (from IgM to IgG or IgA)
and enhanced antibody production. Mice before receiving the
boost, 1 week and 2 weeks after (A–C). The time interval between the
first and the second dose of vaccine was 40 weeks. Each histogram
represents the results (mean6SD) from 3 mice. Conditions of the assay:
A170PG (1.5 mgi n5 0ml/well); pooled serum from A170PG vaccinated
mice (diluted 10
23:5 0ml/well); rat anti mouse-IgG, -IgA or –IgM (diluted
10
23:5 0ml/well); peroxidase substrate (100 ml/well).
doi:10.1371/journal.pone.0028377.g003
Figure 4. A170PG dampens the inflammatory response when used to cure or prevent S. aureus infection in mice. Comparison of the
pro-inflammatory (TNF-a and INF-c) and anti-inflammatory (IL-4 and IL-10) cytokines between groups of mice. Infected vs Vaccinated mice: INF-c,P :
0.01; TNF-a,P :,0.0001; IL-4, P: 0.19; IL-10, P: 0.03. Infected vs Infected and then Treated mice: INF-c, P: 0.03; TNF-a,P :,0.0001; IL-4, P: 0.6; IL-10,
P:0.03.
doi:10.1371/journal.pone.0028377.g004
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confirmed by clinical testing.
Some categories of patients (such as premature neonates and
haemodialysis patients), at high risk of staphylococcal infections,
do not respond adequately to immunization. These patients
benefit particularly from passive immunoprophylaxis. A170PG
antibodies provide passive protection, at least in mice (Table 4). In
vivo, A170PG antibodies display prozone effect (see below), a
property that could not be anticipated on the basis of their
functions in vitro and potentially relevant to passive immunopro-
phylaxis against S. aureus. Purified A170PG antibodies were
protective only when administered within a restricted range: the
dose of 10 ml/mouse rescued all mice (20/20) from a lethal dose of
A170 bacteria (Table 4; experiments 1 and 2); the dose of 20 ml/
mouse of the same preparation instead killed all (20/20) the mice
(Table 4, experiments 3 and 4). Incidentally, the observation that
antibodies are not protective if used in excess is not new and in the
literature the phenomenon is described with the term of ‘‘prozone
effect’’ [21].
In a trial with AltaStaph (a pool of sera from volunteers
immunized with StaphVAX), 24% of the patients treated with
AltaStaph and standard therapy died, compared to 11% of those
treated with the standard therapy alone [19]. The result was
interpreted as evidence of the limited use of the antibodies against
capsular polysaccharides [19]. The data reported above make it
plausible also that failure of AltaStaph might have been caused by
the use of an excess of antibodies (and concurrent prozone effect).
More in general, the prozone effect perhaps deserves careful
consideration when interpreting passive protection experiments.
A170PG exerts its prophylactic activity by inducing antibodies
able to kill bacteria (Figure 2), inhibit organ colonization (Figure 5),
evoke B cell memory (Figure 3) and an anti-inflammatory response
(Figure 4). A170PG has also therapeutic capacity. The vaccine
eradicates infection (even when systemic) with surprising efficacy
and rapidity (Table S3; Table 5). One single dose of vaccine
administered via aerosol to mice previously infected with a lethal
dose of A170 rescued all the mice, while control (infected but not
treated) mice all died (Table 5). In these experiments, mice were
treated with A170PG when severely sick. Still, treated mice all
eradicated the staphylococci within one month from treatment
(Table S3; Table 5 ). In addition, A170PG induced also a strong
anti-inflammatory response (Figure 4). While these results are
Figure 5. A170PG vaccination inhibits mouse organ colonization by S. aureus. Bacteria colonized lungs and kidneys from non-vaccinated
mice, but not the same organs from vaccinated mice. Sections from vaccinated and non-vaccinated mice were incubated (2 h) with Dapi (10 mla t
0.5 mg/ml), fluorescein isothiocyanate (10 ml at 0.5 mg/ml) or neither.
doi:10.1371/journal.pone.0028377.g005
Staphylococcus aureus Peptidoglycan Vaccine
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28377robust evidence of the vaccine’s therapeutic potential, the
mechanisms responsible for the therapeutic efficacy remain
conjectural. Monocytes and macrophages are the main source of
pro-inflammatory cytokines [16]. At the same time they play a
major role also in the antibacterial response [22,23]. This study
shows that macrophage exposure to A170PG suppresses the
production of pro-inflammatory cytokines (Figure 4), but leaves
the antibacterial activity intact, which culminates in the eradica-
tion of the pathogen (Table S3; Table 5). Though seemingly
contradictory, these results become consistent if one assumes that
PG can induce macrophage tolerance, much as LPS does [22].
Exposure to LPS inactivates the macrophage pro-inflammatory
genes, while leaving inducible the antibacterial response genes; this
permits the avoidance of excessive inflammation and septic shock
while fighting pathogens [22]. Here it is proposed that the same
might occur in the case of macrophages exposure to PG. Phrased
another way, PG would dampen inflammation in the case of
Gram-positive infections, just as LPS does in the case of Gram-
negative infections. This hypothesis – though to be confirmed by
future studies - is attractive also because it would explain why PG -
a known bacterial virulence factor [8,9] - is not harmful when used
as vaccine: an excess of PG, as in this study (3–15 mg/mouse), it
would induce desensitization of the downstream inflammation
signalling pathways.
In conclusion, A170PG potentially can find application in the
prophylaxis as well as the therapy of staphylococcal infections, a
rare property for a vaccine. At the same time, one must prudently
consider that A170PG has been tested in a mouse model and the
mouse is not a natural host for S. aureus. Whether this seemingly
promising vaccine will protect humans can only emerge from
clinical trial.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the European Community. The protocol
was approved by the Committee on the Ethics of Animal
Experiments of the University of Naples (Permit Number: 86/
609/EEC). All surgery was performed under sodium pentobarbital
anesthesia, and all efforts were made to minimize suffering.
Bacteria
The sources of the Staphylococcus aureus strains used in the study
are shown in Table S1. The Staphylococcus epidermidis strain and
Listeria monocytogenes strain were collected from patients hospital-
ized at the Medical School of the University of Naples. Molecular
characterization of the S. aureus strains included analysis of the
rDNA V3 spacer region [24], capsular polysaccharide [25],
enterotoxin genes [26,27], Sma 1 restriction endonuclease
analysis [28] and protein A gene (spa) typing [29]. Clinical
samples were streaked on trypticase soy agar (TSA) (Oxoid,
Milan, Italy) and single colonies expanded in trypticase soy broth
(TSB) (Oxoid). For in vivo and in vitro experiments, bacteria
were grown in TSB at 37u C, harvested while in the exponential
growth phase (OD600: 1.5 to 1.8), centrifuged (8610
3 x g for
10 min) and washed with saline (0.15 M NaCl). Serial 10-fold
dilutions in saline were then plated on TSA. To isolate the soluble
form of the peptidoglycan (sPG), the S. aureus strain A170 bacteria
was grown in TSB in the presence of penicillin G (Biopharma,
Italy; 5 mg/ml). When the culture was in the exponential growth
phase, the sPG was isolated from the medium by ConA-Agarose
affinity chromatography.
ConA-Agarose affinity chromatography
CW was extracted from S. aureus, S. epidermidis or L. monocytogenes
with trichloroacetic acid [10] and further purified with concanav-
alin A conjugated to agarose (ConA-Agarose; Sigma, Milan, Italy).
The lectin suspension (500 ml) was centrifuged, washed with Tris-
HCl buffer and the pellet suspended in 500 ml of the same buffer.
CW (2.8 mg in 5 ml Tris-HCl buffer pH 7.5) was mixed with the
ConA-Agarose, incubated for 1 h, centrifuged and the supernatant
(ConA
- fraction) recovered. The pellet was washed three times
with Tris-HCl buffer and the CW eluted from the matrix with
5 ml of 0.2 M a-methyl-diglucoside (Sigma) (ConA
+CW fraction).
The ConA
-CW and ConA
+CW fractions were desalted (Sephadex
G-25), lyophilized, weighed and tested separately for the capacity
to protect mice.
Mice
Experiments were carried out on female Balb/c mice (aged 8 to
10 weeks) at the animal facility of the University of Naples. Mice
infection and vaccination were carried out via the intramuscular,
intravenous or aerosol routes. For intramuscular or intravenous
infection, individual mice were injected with 10
8 colony forming
units (CFU)/100 ml saline. For aerosol infection, five mice were
placed in a nebulizing chamber and exposed to the aerosol
bacterial suspension (10
6 to 10
8 CFU/100 ml saline). The Con-
A
+CW fraction from the S. aureus strains A170 was administered
intramuscularly (3–15 mgi n5 0ml/mouse) or by aerosol (3–15 mg/
50 ml saline/mouse). Organs were dissected and weighed. Samples
were homogenized in 1 ml saline and serially diluted in the same
medium. CFU were evaluated by the plate count assay and
expressed as CFU/g.
Detection of ConA
+CW antibodies
The wells of a 96-well plate (Falcon, Milan) were coated with
the antigen being tested: muramic acid (MA), pentaglycine (Gly
5),
ribitol (RBT), lipoteichoic acid (LTA) (all from Sigma); ConA
+ or
ConA
- fractions of the CW from S. aureus, S. epidermidis or L.
monocytogenes; soluble peptidoglycan (sPG). Antigens were used at
0.1–15 mgi n5 0ml/well. The plate was quenched with 3% bovine
serum albumin (50 ml/well; 2 h), washed with PBS, incubated
overnight with purified antibodies from mice immunized with
ConA
+CW (diluted 10
22–10
24;5 0 ml/well). Antibodies were
purified by protein A affinity chromatography [30] and brought
to 50 mg/ml. Plates were washed with PBS and incubated, in
succession, with peroxidase-labelled secondary antibodies (rat anti
total mouse immunoglobulin, rat anti mouse-IgG, -IgM or -IgA
diluted 10
23 (50 ml/well; 2 h; Sigma) and peroxidase substrate
(100 ml/well; 1 h; Bio-Rad, Milan). Optical density (OD) was
measured at 600 nm. Samples were run in triplicate.
Other methods
To test the biological activity of the A170PG, S. aureus A170
bacteria (10
7 CFU/100 ml saline) were incubated (1 h at 37uC)
with 5 ml of A170PG purified antibodies or with 5 ml of the same
antibodies plus 5 ml of complement (BioMerieux, France). CFU
were evaluated by the plate count assay. ConA
+CW (0.28 mg in
500 ml Tris-HCl pH7.5) was digested with lysozyme (Sigma;
220 U/ml; 2 h) or lysostaphin (Sigma; 220 U/ml; 2 h) and then
used to immunize mice (50 ml/mouse). The transcription level of
mouse cytokine genes was analyzed by real-time reverse
transcription PCR (RT-PCR) as described [31]. Survival rates of
mice were analyzed using the Kaplan-Meier test. Bacterial counts
and gene expression levels were analyzed using the paired t test (P
values are two-tailed values).
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Figure S1 Cross-reaction of PG preparations from L.
monocytogenes (A), S. epidermidis (B) and S. aureus (C).
Conditions of the ELISA assay 1.5 mg PG preparation in 50 ml/
well; serum from mice immunized with A170PG diluted 10
23:
50 ml/well; rat anti mouse IgG diluted 10
23:5 0ml/well.
(TIF)
Figure S2 Kaplan-Meier survival curves of mice vacci-
nated with A170PG (3 mg/mouse) by the aerosol, intra-
muscular or intravenous routes. Vaccinated and control
mice were challenged with 10
8 CFU/mouse.
(TIF)
Table S1 Molecular characterization of S. aureus
strains.
(DOC)
Table S2 Broad protective activity of the A170PG
vaccine.
(DOC)
Table S3 Aerosol administration of A170PG eradicates
S. aureus systemic infection.
(DOC)
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